A grow in g b ody o f evidence, includ ing stud ies using genetically engineered m ouse m odels, has show n that C a 2+ cycling and C a 2+ -dependent sign alin g p ath w ays p lay a p ivo tal ro le in card iac hypertrophy and heart failure. In addition, recent stu d ies id en tified th at m u tatio n s o f th e g en es encodin g sarco plasm ic reticu lum (S R ) p rotein s cau se h um an card iom yopathies an d leth al ventricu lar arrhyth m ias. The reg ulatio n of C a 2+ hom eostasis via the SR proteins m ay have potential therapeutic value for heart diseases such as cardiom yopathy, heart failure and arrhythm ias.
Introduction
Calcium is not only indispensable for normal muscle contraction and relaxation but also important as a second messenger of various signaling pathways in the heart. A growing body of evidence has shown that Ca 2+ homeostasis and Ca 2+ -dependent signaling pathways play a pivotal role in the development of cardiac hypertrophy, heart failure and arrhythmias. In this regard, two issues regarding the role of Ca 2+ in the heart are attracting considerable attention. One is the discovery of Ca 2+ /calmodulin-dependent calcineurin signaling pathway in cardiac hypertrophy (Olson and Williams, 2000; Wilkins and Molkentin, 2002 ) and the other is to identify the critical role of cardiac Ca 2+ cycling in cardiomyopathy, heart failure and arrhythmias (Chien, 2000; Houser et al., 2000; Scoote and Williams, 2002) . In this review, we focus on the latter topic, especially on Ca 2+ cycling proteins in the sarcoplasmic reticulum (SR).
The regulation of C a 2+ release an d uptake via the cardiac sarcoplasm ic reticu lu m Periodic changes in Ca 2+ concentration in cardiomyocytes are essential for cardiac contraction and relaxation, and the intracellular Ca 2+ concentration is integrally regulated by proteins associated with the SR, an extensive intracellular membrane system. The SR consists of lipid bilayer organelle that surrounds each myofibril. In response to membrane depolarization, a small amount of extracellular Ca 2+ enters the cardiomyocyte through the L-type Ca 2+ channels. The Ca 2+ influx triggers the release of Ca 2+ from the SR into the cytosol through the cardiac ryanodine receptor (RyR2), initiating cardiac contraction. This event is known as Ca 2+ induced-Ca 2+ release. The relaxation is predominantly mediated by Ca 2+ sequestration from the cytosol into the SR lumen via the SR calcium ATPase 2a (SERCA2a). The activity of the RyR2 and SERCA2a are known to be under fine-tuning by their intrinsic regulatory domains and associated SR proteins.
The RyR2 forms homotetramers consisting of 4 monomeric subunits, each of about 565-kDa to produce a bona fide ion channel. The subunit contains a high-conductance Ca 2+ -selective pore, Ca 2+ activation and inactivation sites, several phosphorylaCalcium cycling proteins in heart failure, cardiom yopathy and arrhythm ias tion sites, and multiple binding sites for a myriad of endogenous regulators including ATP, Mg 2+ , and calmodulin. The RyR2 also forms a macromolecular complex by protein-protein interactions, including protein kinase A (PKA) and its anchoring protein (mAKAP), the protein phosphatases PP1 and PP2A, sorcin, calmodulin, a FK506 binding protein (FKBP12.6), and other proteins in the cytosol (Marks et al., 2002a) . In the luminal region of junctional SR membrane, the RyR2 is also associated with cardiac calsequestrin (CSQ), triadin, junctin, and junctate, which are all required for appropriate regulation of the Ca 2+ release from the RyR2 (Muller et al., 2002) . Although cAMP-dependent PKA signal pathway plays the most important role in the regulation of the RyR-mediated Ca 2+ release, the function of the RyR2 is regulated by many other factors, including several regulatory domains and protein-protein interactions with many molecules.
CSQ is a 55-kDa high capacity, moderate affinity Ca 2+ -binding protein localized to the lumen of the junctional SR in cardiac muscle. CSQ forms a dense matrix in the SR lumen, where the protein appears to be physically connected to the RyR2 by anchoring strands. Biochemical evidence suggests that CSQ actively participates in muscle contraction by regulating the amount of luminal Ca 2+ store (Sitsapesan and W illiams, 1997) . This regulatory effect of CSQ may be mediated by CSQ-anchoring proteins such as triadin and junctin (Zhang et al., 1997) . Triadin was first identified as a 95-kDa protein in skeletal muscle junctional SR membrane (Caswell et al., 1991) and subsequently three cardiac triadin isoforms (triadin 1, 2 and 3) were cloned. Junctin was originally identified as a 26-kDa major CSQ-binding protein in cardiac and skeletal muscle junctional SR membranes (Jones et al., 1995) . Although triadin and junctin are the products of different genes, they exhibit intriguing structural and amino acid sequence similarities and play an important role in the regulation of Ca 2+ release from the RyR2. Junctate, an alternative splicing form of the same gene generating junctin and aspartyl β-hydroxylase, is a newly identified 33-kDa Ca 2+ binding protein in the integral SR membrane and three cardiac isoforms (junctate 1, 2 and 3) were cloned from the mouse heart (Treves et al., 2000; Hong et al., 2001) .
Crosstalk between L-type Ca 2+ channels on the sarcolemmal membrane and the RyR2 on the SR is a fundamental feature of excitation-contraction (EC) coupling in the heart. Junctophilin type 2 (JP2), a cardiac isoform of JP family, has been recently identified as a membrane spanning protein that contributes to the formation of the junctional membrane complexes between the sarcolemmal membrane and the SR (Takeshima et al., 2000) . JP2 is an essential component for the stabilization of the junctional membrane complexes and may play an important role in maintaining normal functional coupling of Ca 2+ induced-Ca 2+ release. SERCA2a, a cardiac and slow-twitch skeletal muscle isoform of SERCA family that belongs to P-type ATPases, is the primary regulator of the rate of Ca 2+ re-uptake during relaxation in the heart (Periasamy and Huke, 2001 ). The activity of SERCA2a is mainly regulated by its endogenous inhibitor, phospholamban (PLN). PLN, a 52 amino acid SR transmembrane phosphoprotein, inhibits Ca 2+ uptake to interact with SERCA2a at their cytoplasmic and transmembrane domains. Phosphorylated PLN relieves its inhibition on SERCA2a activity, resulting in an increase in Ca 2+ uptake into the SR (Frank and Kranias, 2000) .
Sarcolipin has been identified as a counterpart of PLN in skeletal muscle (Odermatt et al., 1998) . The expression of mouse sarcolipin mRNA, however, was most abundant in the atria and was undetectable in the ventricles, indicating an atrial chamber-specific expression pattern in the heart (Minamisawa et al., 2003b) . Atrial chamber-specific expression of sarcolipin mRNA was increased during development and was down-regulated in the atria of hypertrophic heart. In human, sarcolipin mRNA was also expressed in the atria, but not detected in the ventricles. Therefore, sarcolipin is likely to be an atrial chamber-specific regulator of Ca 2+ cycling in the heart. It is intriguing to know whether sarcolipin plays an important role in the atrium-specific cardiac disorders such as atrial fibrillation.
Sarcalumenin is a Ca 2+ -binding protein localized in the longitudinal SR. Sarcalumenin isoforms are generated as 160-and 53-kDa glycoproteins by the alternative splicing of the primary transcript derived from its gene, and are specifically expressed in skeletal and cardiac muscle cells (Leberer et al., 1990) . The amino-terminal half of the 160-kDa isoform is characterized by the juxtapositions of negatively charged residues resembling to that of CSQ. Although several studies have suggested that sarcalumenin works as a Ca 2+ -buffering protein like CSQ and regulates SERCA activity (Martin, 1990) , the physiological role of sarcalumenin remains largely unknown at the present.
The functional relevance between β-adrenergic sysytem/cAMP-dependent PKA signal pathway and Ca 2+ cycling in the heart has been warranted ( Figure  1 ). cAMP-dependent PKA signal pathway plays a pivotal role in the regulation of Ca 2+ release and uptake in the SR. Marx et al. demonstrated that the phosphorylated RyR2 by PKA is dissociated from FKBP12.6, resulting in pronounced channel open probability. Furthermore, the hyperphosphorylated RyR2 increased SR Ca 2+ leak from the SR in patients with heart failure (Marx et al., 2000) . Yano et al. also found that the binding of FKBP12.6 to the RyR2 was decreased in pacing-induced heart failure when compared with normal hearts (Yano et al., 2000) . As to Ca 2+ uptake into the SR, phosphorylation at PLN serine-16 by PKA is the predominant event leading to a proportional increase in the rate of Ca 2+ uptake and accelerates ventricular relaxation (Colyer, 1998) . PLN is considered to be mostly responsible for the effects of β-adrenergic stimulation on cardiac contractility and relaxation, since PLN deficient mice display the maximal contraction without β-adrenergic stimulation (Luo et al., 1994) . A decrease in PLN phosphorylation has been demonstrated in patients or animal models of heart failure, resulting in a decrease in Ca 2+ uptake into the SR (Schmidt et al., 1999; Sande et al., 2002) . Therefore, abnormal β-adrenergic/cAMP-dependent PKA signal pathway induces the imbalance of Ca 2+ release and uptake in the SR, resulting in the reduced Ca 2+ content in the SR. This is a central physiological hallmark of a number of animal models of heart failure, as well as in human failing hearts.
G enetically engineered anim al m odels
Genetically engineered mice, such as transgenic and knockout mice, have proved to be extremely useful for understanding the regulation of many molecules involved in EC coupling and Ca 2+ cycling in the heart, and have given strong insights for pathophysiological roles of the SR proteins Dillmann, 1999) . (Takeshima et al., 1998) . Alterations in RyR2 accessory proteins are also associated with pathogenesis in the heart. Ablation of FKBP12.6 gene caused cardiac hypertrophy in male mice, but not in female, despite the similar dysregulation of Ca 2+ release in male and female knockout mice (Xin et al., 2002) . FKBP12.6-null mice consistently exhibited exercise-induced cardiac ventricular arrhythmias that cause sudden cardiac death. (Wehrens et al., 2003) . Since FKBP 12.6 stabilizes RyR2 channel activity and prevents aberrant activation of RyR2 during the resting phase of the cardiac cycle, this data suggests that unstable RyR2 channel can induce life-threatening arrhythmias. Although FKBP12 is predominantly associated with skeletal RyR (RyR1), FKBP12-deficient mice displayed severe dilated cardiomyopathy and ventricular septal defects without abnormality in skeletal muscle (Shou et al., 1998) .
Sorcin is a penta-EF hand Ca 2+ -binding protein that binds directly to both RyR2 and the L-type Ca 2+ channel. The transgenic mice exhibited no cardiac hypertrophy and no change in expression of other calcium regulatory proteins. However, significant reductions in global indices of contraction and relaxation were observed in the transgenic hearts. In addition, Ca 2+ transient amplitudes were significantly depressed and the Ca 2+ currents (ICa) inactivation rate of the L-type Ca 2+ channel was significantly accelerated in transgenic myocytes (Meyers et al., 2003) .
Overexpression of the junctin under the control of α-myosin heavy chain promoter caused bi-atrial and bi-ventricular enlargements, impaired LV systolic function, bradycardia, atrial fibrillation, and increased fibrosis (Zhang et al., 2001; Hong et al., 2002; Kirchhefer et al., 2003) . Transgenic mice overexpressing triadin 1 in atria and ventricles demonstrated cardiac hypertrophy and impaired contractility and relaxation (Kirchhefer et al., 2001) . Cardiac-specific overexpression of junctate 1 resulted in dilated cardiomyopathy with severely depressed LV systolic function and various arrhythmias such as atrial fibrillation, ventricular premature beats and sinus pause. The reduced SR Ca 2+ content, enhanced L-type Ca 2+ current density, and the prolonged action potential duration may account for the bradycardia in the junctate 1 transgenic heart (Cho et al., 2003) . Thus, the transgenic mice with cardiac-specific overexpression of triadin 1, junctin and junctate 1 show distinct cardiac phenotypes, suggesting that these junctional SR transmembrane proteins are of functional relevance for the regulation of the SR Ca 2+ release in the heart. To elucidate the physiological significance of cardiac CSQ (CSQ2) in the cardiac excitation-contraction coupling, two independent lines of transgenic mice overexpressing CSQ2 in the heart have been generated (Jones et al., 1998; Sato et al., 1998) . Although cardiac-targeted overexpression of CSQ2 results in a marked increase in SR Ca 2+ storage in the both models, SR Ca 2+ release was impaired upon depolarization, leading to depressed contractile parameters and cardiac hypertrophy. Transition from concentric LV hypertrophy to overt heart failure was clearly demonstrated and defective β-adrenergic receptor signaling preceded the development of dilated cardiomyopathy (Cho et al., 1999) . These findings suggest that chronic suppression of Ca 2+ release caused by overexpression of CSQ2 or the excess amount of CSQ2 per se also initiate a cascade of molecular events that activates the program of cardiac hypertrophy and/or heart failure. In contrast, no phenotypic feature of heart failure was observed up to 17 months of age in ventricles of the model of Sato et al., which expresses higher amount of CSQ2 in the myocardium, suggesting that endogenous traits of the mouse strains also influence the outcomes (Sato et al., 2003) .
The genetic ablation of JP2 in mice caused wider gap size of the junctional membrane complexes and deficient [Ca 2+ ]i transients in cardiomyocytes, resulting in embryonic lethality (Takeshima et al., 2000) . These findings indicate that JP2 is essential to form normal junctional membrane complexes and efficient Ca 2+ induced-Ca 2+ release in the heart. The expression of JP2 was up-regulated during normal development and was down-regulated in a hypertrophic or dilated cardiomyopathic mouse model (Minamisawa et al., unpublished data) . JP type 1 (JP1) is a skeletal muscle type of JP isoforms. JP1 knockout mice died shortly after birth and exhibited deficiency of triad junctions and contraction in skeletal muscles (Ito et al., 2001) . Transgenic mice overexpressing JP1 exibted abnormal junctional membranes, in which the T-tubules were rolled up with the SR membranes. However, authentic triad formation was not induced by JP1 overexpression in cardiac myocytes, suggesting that ectopic JP1 expression cannot convert the diad to the triad in cardiac myocytes (Komazaki et al., 2003) .
Two independent groups generated transgenic mice overexpressing SERCA2a in the heart. The increase in SERCA2a expression resulted in myocardial contractility and relaxation by increasing SR Ca 2+ transport (He et al., 1997; Baker et al., 1998) . Transgenic mice overexpressing a high calcium affinity SERCA2a mutant (K397/400E), lacking a functional association with PLN, were also generated. The transgenic mouse hearts showed increased contraction and relaxation, with increases in the amplitude of Ca 2+ transient and rapid Ca 2+ decay (Nakayama et al., 2003) . Moreover, transgenic mice overexpressing the fast-twitch skeletal muscle type of SERCA (SERCA1a) (Loukianov et al., 1998 ) or SERCA2b (Greene et al., 2000 in a heart-specific manner were also generated. Both mice demonstrated enhanced myocardial contractility and increased Ca 2+ transport function, indicting that both SERCA isoforms can substitute for SERCA2a in vivo.
Complete ablation of SERCA2 (both SERCA2a and 2b) resulted in embryonic lethality (Periasamy et al., 1999) . Heterozygous mutant hearts that expressed 65% of the protein levels of SERCA2 compared with wild-types showed impaired cardiac contractility and relaxation (Ji et al., 2000) . When SERCA2a gene was specifically ablated, homozygous mutant hearts expressed only SERCA2b of which the protein levels were reduced to 40% of total SERCA2 in wild-type mice. SERCA2a deficiency led to increased incidence of perineonatal mortality and cardiac structural malformations as well as mild cardiac hypertrophy with impaired cardiac contractility and relaxation (Ver Heyen et al., 2001) . This data indicates that SERCA2a is essential for normal cardiac development and function.
Transgenic mice expressed two-fold higher levels of PLN in the heart displayed impaired cardiac contractility and relaxation without any phenotypic alterations including heart-to-body mass ratio, cardiomyocyte size and morphology (Kadambi et al., 1996) . However, transgenic mice overexpressing PLN at 4-fold normal levels exhibited the development of overt heart failure and a premature mortality with aging (Dash et al., 2001) . To elucidate whether the site-specific mutations of PLN alter cardiac contractility and relaxation, more than 10 transgenic mice overexpressing various types of mutant PLN have been also generated (Chu et al., 1998; Brittsan et al., 2000; Zvaritch et al., 2000; Haghighi et al., 2001; Hoshijima et al., 2002; Schmidt et al., 2002; Schmitt et al., 2003) . Among them, an increase in cardiac contractility and relaxation is detected only in the transgenic mice overexpressing a S16E peudo-phosphorylated PLN mutant (Hoshijima et al., 2002) . Several transgenic mice exhibited impaired cardiac contractility and relaxation, resulting in cardiac remodeling such as cardiac hypertrophy (Zvaritch et al., 2000) and heart failure (Haghighi et al., 2001; Schmidt et al., 2002; Schmitt et al., 2003) .
Mice heterozygous and homozygous for the PLNablated gene have been extensively evaluated by Dr.
Kranias and her colleagues . Reduction or ablation of PLN resulted in "supernormal" cardiac contraction and relaxation without any phenotypic alterations at the gross morphology or ultrastructural levels in mice (Luo et al., 1994) .
H um an cardiom yopathy caused by genetic m utations in C a 2+ cyclin g m olecules
Cardiomyopathy is defined as a disease of the myocardium associated with cardiac dysfunction by either intrinsic/genetic disorders of myocardium, or extrinsic specific events like ischemia, pressure and volume overloads, abnormal metabolism, inflammation or toxic agents. Primary cardiomyopathy is a group of intrinsic disorders of the myocardium. To date, more than 20 genes have been identified as being responsible for cardiomyopathy. Despite the diverse etiologies, Ca 2+ cycling defect is a physiological hallmark of all forms of cardiomyopathy. Therefore, the genes involved in Ca 2+ cycling have been considered responsible for cardiomyopathy, and candidate gene approach has been employed in many laboratories.
In this regard, mutations in the RyR2 have been identified as the cause of arrhythmogenic right ventricular dysplasia (ARVD), a specific type of cardiomyopathy . This is the first SR gene which causes cardiomyopathy. Mutations in the RyR2 also cause cathecholamine-induced polymorphic ventricular tachycardias (Marks et al., 2002b) . These data indicate that RyR2 is responsible not only for cardiomyopathy and heart failure, but also for life-threatening arrhythmias.
Two independent groups have recently found that mutations of the PLN gene cause human dilated cardiomyopathy. One is a missense mutation at residue 9 (Arg Cys) which is proposed to block PKA-mediated phosphorylation of PLN (Schmitt et al., 2003) . The other is a nonsense mutation at residue 39 (Leu stop) (Haghighi et al., 2003) . In the former study, they generated Arg9Cys mutant PLN transgenic mice, in which PKA-mediated phosphorylation of PLN at serine 16 was blocked. The decay of Ca 2+ transient was delayed in mutant myocytes, indicating impaired Ca 2+ uptake. The mice recapitulated human heart failure. In the latter study, the heterozygous individuals with Leu39stop mutation exhibited hypertrophy without decreased contractile performance, and individuals homozygous displayed the diminished expression of PLN in the SR (null PLN) and dilated cardiomyopathy. The authors claimed that PLN is essential to maintain normal cardiac function in human, in contrast to mice in which PLN deficiency enhances cardiac contractility and relaxation without any adverse effects. These opposite results from different species have to be verified in detail, since, as we will discuss later, PLN is thought to be one of the prime targets for novel therapeutic invention of heart failure.
In addition, a single nucleotide transition, -77A G, in the PLN promoter region was found in a patient with late-onset type of hypertrophic cardiomyopathy (Minamisawa et al., 2003a) . The mutation was found to increase PLN promoter activity using neonatal rat myocytes, suggesting that -77A G mutation in the PLN promoter region increases the PLN expression in the heart. The mutation has not been found more than normal 300 individuals so far. Therefore, the mutation in the promoter region may play an important role in the development of hypertrophic cardiomyopathy in human. Since different mutations in several sarcomeric proteins such as β-myosin heavy chain and troponin T cause dilated and hypertrophic cardiomyopathies (Seidman and Seidman, 2001) , PLN is also likely to be associated with both dilated and hypertrophic cardiomyopathies. Here, the genes involved in Ca 2+ cycling have become the real candidates responsible for cardiomyopathy. It should be intriguing to investigate mutations of other SR genes in patients with cardiomyopathy.
Life-threatening ventricular arrhythm ias caused by genetic m utations in C a

2+ cycling m olecules
A growing body of evidence indicates that mutations of RyR2 and CSQ2 cause catecholaminergic polymorphic ventricular tachycardia (CPVT) and ARVD2 (Lahat et al., 2001; Laitinen et al., 2001; Bauce et al., 2002; Postma et al., 2002; Priori et al., 2002; Lahat et al., 2003) . Although the molecular mechanisms underlining the relation between genotypes and phenotypes remain unclear, one may assume that the greater amount of Ca 2+ release from the mutant hearts may induce an elevated diastolic cytoplasmic Ca 2+ during exercise-or catecholamine-induced stress, resulting in diastolic afterdepolarizations that can initiate fatal ventricular tachyarrhythmias. This increased Ca 2+ release can be mediated by FKBP12.6. Recently, Wehrens et al demonstrated that a derivative of 1,4-benzothiazepine (JTV519) increased the affinity of FKBP12.6 for RyR2, which stabilized the closed state of RyR2 and prevented the Ca 2+ leak that triggers arrhythmias (Wehrens et al., 2004) . Thus, further investigation of mutations in other SR genes related to Ca 2+ release such as FKBP12.6, triadin 1 and junctin will be warranted.
The m odulation of the S R proteins is potential therapeutic strategy for cardiom yopathy, heart failure, and arrh yth m ias
Our current therapy for cardiomyopathy and heart failure is primarily palliative and is not biologically targeted because of poor understanding in stress pathways leading to the progression of cardiac muscle dysfunction. The lessons from animal studies and human genetics revealed, however, that a decrease in Ca 2+ uptake due to reduced SERCA2a activity and an increase in Ca 2+ leak from the SR due to instability of the RyR2 play an important role in the development of cardiomyopathy, heart failure and arrhythmias. Therefore, the restore of the SR function may be novel therapeutic strategy for these abnormalities.
Genetic approaches and pharmacological interventions, designed to increase SERCA2a activity or inhibit PLN function, may prove valuable in preventing or reversing the adverse physiological impairment in cardiomyopathy and heart failure. It may be a fundamental approach to increase SERCA2a activity by simply increasing the expression level of SERCA2a. This can be achieved through SERCA2a gene transfer. Dr. Hajjar's group demonstrated that muscle contractility and relaxation were restored by adenovirus-mediated SERCA2a gene transfer in an animal model of pressure overload (Miyamoto et al., 2000) as well as in cardiomyocytes from patients with heart failure (del Monte et al., 2001) . They recently demonstrated that improving intracellular Ca 2+ cycling by overexpression of SERCA2a restored contractile function and reduced ventricular arrhythmias during cardiac ischemia-reperfusion (del Monte et al., 2004) .
Inhibition of PLN function or disruption of the interaction between PLN and SERCA2a is an alternative way to increase SERCA2a activity. Reduction of PLN expression by decreasing PLN transcription, or disrupting PLN mRNA stability seems to have promising value for pharmaceutical interventions to improve cardiac performance. Adenovirus-mediated antisense expression of PLN coding region resulted in the successful depression of PLN mRNA and protein and increased Ca 2+ uptake in neonatal rat myocytes (He et al., 1999; Eizema et al., 2000) . Inhibitory RNA (iRNA) for PLN mRNA can be an alternate to decrease PLN protein in the heart. Recent studies demonstrated that certain PLN mutants increased contractility and relaxation of normal and pathological hearts when they were transferred into myocytes and animal hearts using adenovirus or adeno-associated vector (Minamisawa et al., 1999; Hoshijima et al., 2002; Iwanaga et al., 2004) . Therefore, selective disruption of the interaction between SERCA2a and PLN is effective to prevent or reverse cardiac performance in dilated cardiomyopathy and heart failure. So far augmented SERCA2a activity has beneficial effects on the cardiac function in rodent models of heart failure. This can be a novel inotropic therapy for cardiac dysfunction, at least for a short period. However, it should be carefully evaluated whether augmented SERCA2a activity affects morbidity and mortality in human for a long period, since a null PLN mutation causes dilated cardiomyopathy in human described above (Haghighi et al., 2003) .
In addition to reduced SR Ca 2+ uptake, increased Ca 2+ leak through RyRs is a significant component of altered EC coupling in heart failure. (Prestle et al., 2001) . Yao et al. recently reported that the prevention of Ca 2+ leak through RyRs improved ventricular function and prevention of heart failure in a dog model, using the agent JTV519, which restores the FKBP12.6-mediated stabilization of RyR (Yano et al., 2003) . JTV519 also prevented fetal ventricular arrhythmias caused by the Ca 2+ leak from the RyR2 (Wehrens et al., 2004) . Therefore, reducing SR leak is a promising approach to improve Ca 2+ cycling of the failing heart as well as arrhythmias.
More than 100 years after Ringer's discovery indicating that Ca 2+ is essential for normal muscle contraction, we have been realizing that the modulation of intracellular Ca 2+ concentration via manipulating the SR proteins is promising tactics to fight a monster syndrome, "heart failure".
